AU2018380132B2 - Tubulin inhibitors - Google Patents

Tubulin inhibitors Download PDF

Info

Publication number
AU2018380132B2
AU2018380132B2 AU2018380132A AU2018380132A AU2018380132B2 AU 2018380132 B2 AU2018380132 B2 AU 2018380132B2 AU 2018380132 A AU2018380132 A AU 2018380132A AU 2018380132 A AU2018380132 A AU 2018380132A AU 2018380132 B2 AU2018380132 B2 AU 2018380132B2
Authority
AU
Australia
Prior art keywords
formula
alkyl
compound
halogen
nrrd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018380132A
Other languages
English (en)
Other versions
AU2018380132A1 (en
AU2018380132A8 (en
Inventor
Jessica CRISP
Tom Lin
Jason OLEJNICZAK
Richard Truong
Cheng-Chi Irene Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lin Bio Inc
Original Assignee
Lin Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lin Bio Inc filed Critical Lin Bio Inc
Publication of AU2018380132A1 publication Critical patent/AU2018380132A1/en
Publication of AU2018380132A8 publication Critical patent/AU2018380132A8/en
Assigned to Lin Bioscience, Inc. reassignment Lin Bioscience, Inc. Request for Assignment Assignors: Lin Bioscience, Pty Ltd.
Application granted granted Critical
Publication of AU2018380132B2 publication Critical patent/AU2018380132B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Epoxy Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Indole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018380132A 2017-12-06 2018-12-05 Tubulin inhibitors Active AU2018380132B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762595530P 2017-12-06 2017-12-06
US62/595,530 2017-12-06
PCT/US2018/064114 WO2019113242A1 (en) 2017-12-06 2018-12-05 Tubulin inhibitors

Publications (3)

Publication Number Publication Date
AU2018380132A1 AU2018380132A1 (en) 2020-06-18
AU2018380132A8 AU2018380132A8 (en) 2020-07-09
AU2018380132B2 true AU2018380132B2 (en) 2023-11-09

Family

ID=66658388

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018380132A Active AU2018380132B2 (en) 2017-12-06 2018-12-05 Tubulin inhibitors

Country Status (8)

Country Link
US (3) US11040945B2 (OSRAM)
EP (1) EP3720436A4 (OSRAM)
JP (1) JP7319977B2 (OSRAM)
KR (1) KR20200104873A (OSRAM)
CN (1) CN111727042A (OSRAM)
AU (1) AU2018380132B2 (OSRAM)
TW (1) TWI828644B (OSRAM)
WO (1) WO2019113242A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019200683B2 (en) * 2018-02-01 2024-05-30 The University Of Sydney Anti-cancer compounds
JP7184383B2 (ja) * 2018-02-01 2022-12-06 ザ・ユニバーシティ・オブ・シドニー 抗癌性化合物
MX2021006731A (es) 2018-12-07 2021-09-23 Univ Maryland Inhibidores de proteínas quinasas activadas por mitógeno p38 en sitio no atp/catalítico.
MX2022001151A (es) * 2019-07-31 2022-02-22 Aclaris Therapeutics Inc Inhibidores deuterados de la via mk2 y metodos de uso de los mismos.
US20210147441A1 (en) * 2019-09-26 2021-05-20 Agency For Science, Technology And Research (A*Star) Therapeutic compounds and methods of use thereof
CN114980887A (zh) 2019-12-20 2022-08-30 特纳亚治疗股份有限公司 氟代烷基-噁二唑及其用途
BR112022019349A2 (pt) 2020-03-27 2022-11-16 Aclaris Therapeutics Inc Forma cristalina, composição farmacêutica, comprimido e método para isolar um composto
WO2022103149A1 (ko) * 2020-11-10 2022-05-19 주식회사 큐라클 신규한 카바졸 유도체 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
JP7659650B2 (ja) * 2021-03-23 2025-04-09 ジーニー ライフサイエンシズ インコーポレイテッド 置換ナフチルｐ３８アルファマイトジェン活性化プロテインキナーゼ阻害剤
WO2022235842A1 (en) 2021-05-04 2022-11-10 Tenaya Therapeutics, Inc. 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016119017A1 (en) * 2015-01-30 2016-08-04 The University Of Sydney Anti-cancer compounds

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2205732A1 (de) 1972-02-08 1973-08-16 Thomae Gmbh Dr K Neue 4-(4-biphenylyl)-butensaeurederivate
IT1044222B (it) 1972-05-23 1980-03-20 Zambeletti Spa L Bifenilil alcanoilaminopiridine ad attivita anti infiammatoria di lunga durata
AT336594B (de) 1973-08-14 1977-05-10 Thomae Gmbh Dr K Verfahren zur herstellung neuer 3-(4- biphenylyl)-buttersaureamiden
US5196543A (en) 1989-10-17 1993-03-23 Delalande S.A. 3-aryloxazolidinone derivatives, process for their preparation and their use in therapy
AU643542B2 (en) 1990-06-14 1993-11-18 Monsanto Company RNA hydrolysis/cleavage
JP2969618B2 (ja) * 1995-06-27 1999-11-02 田辺製薬株式会社 ピリダジノン誘導体及びその製法
US5756507A (en) 1995-12-14 1998-05-26 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
JP3060454B2 (ja) * 1996-12-26 2000-07-10 田辺製薬株式会社 医薬組成物
WO2001012189A1 (en) 1999-08-12 2001-02-22 Pharmacia Italia S.P.A. 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
US6114365A (en) 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
ES2193839B1 (es) 2001-06-22 2005-02-16 Almirall Prodesfarma, S.A. Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
PT2277865E (pt) 2003-12-03 2015-02-05 Ym Biosciences Australia Pty Heterociclos de azoto de anel de 6 membros fenil substituídos como inibidores de polimerização de microtúbulos
AU2005247906B2 (en) 2004-05-18 2011-08-25 Merck Sharp & Dohme Corp. Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors
CN101052398A (zh) * 2004-10-29 2007-10-10 默克公司 作为雄激素受体调节剂的n－(吡啶－3－基)－2－苯基丁酰胺
PT1861365E (pt) * 2005-03-15 2009-09-22 4Sc Ag N-sulfonilpirroles e a sua utilização como inibidores de histona-desacetilase
US20070254913A1 (en) 2006-04-19 2007-11-01 Dunn Robert F Phosphodiesterase 4 inhibitors
EP2038272B8 (en) 2006-06-30 2013-10-23 Sunesis Pharmaceuticals, Inc. Pyridinonyl pdk1 inhibitors
JP2009185010A (ja) 2008-02-08 2009-08-20 Taisho Pharmaceutical Co Ltd グリシントランスポーター阻害剤を含有する医薬
FR2933700B1 (fr) * 2008-07-08 2010-07-30 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
BR112012003661A2 (pt) * 2009-08-19 2017-04-25 Ambit Biosciences Corp "compostos de biarila e métodos de uso dos mesmos."
FR2952934B1 (fr) 2009-11-23 2012-06-22 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
US8518948B2 (en) * 2010-03-10 2013-08-27 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
ES2572387T3 (es) 2010-03-18 2016-05-31 Pasteur Institut Korea Compuestos anti-infecciosos
EP3111937B1 (en) 2011-07-08 2020-06-17 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for treatment of liver cancer
US20130267712A1 (en) 2012-04-02 2013-10-10 Board Of Trustees Of Northern Illinois University Aromatic ketone synthesis with amide reagents and related reactions
CN105473559B (zh) 2013-03-15 2019-05-10 南洋理工大学 用于化学转化的羰基β-碳的活化
AR098475A1 (es) 2013-11-26 2016-06-01 Bayer Cropscience Ag Compuestos pesticidas y usos
WO2016067009A1 (en) 2014-10-28 2016-05-06 Redx Pharma Plc Compounds with activity against bacteria and mycobacteria
WO2016193939A1 (en) 2015-06-04 2016-12-08 Aurigene Discovery Technologies Limited Substituted heterocyclyl derivatives as cdk inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016119017A1 (en) * 2015-01-30 2016-08-04 The University Of Sydney Anti-cancer compounds

Also Published As

Publication number Publication date
JP2021508318A (ja) 2021-03-04
AU2018380132A1 (en) 2020-06-18
WO2019113242A1 (en) 2019-06-13
US11040945B2 (en) 2021-06-22
CN111727042A (zh) 2020-09-29
US20190169127A1 (en) 2019-06-06
TWI828644B (zh) 2024-01-11
KR20200104873A (ko) 2020-09-04
JP7319977B2 (ja) 2023-08-02
US20220089539A1 (en) 2022-03-24
AU2018380132A8 (en) 2020-07-09
US12247010B2 (en) 2025-03-11
EP3720436A1 (en) 2020-10-14
TW201930266A (zh) 2019-08-01
EP3720436A4 (en) 2021-06-02
US20250188035A1 (en) 2025-06-12

Similar Documents

Publication Publication Date Title
US12247010B2 (en) Tubulin inhibitors
CA2915561C (en) Novel substituted bicyclic compounds as bromodomain inhibitors
CA2710043C (en) Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
CA3219348A1 (en) Checkpoint kinase 1 (chk1) inhibitors and uses thereof
EP2476679B1 (en) Substituted triazoles useful as AXL inhibitors
CA2710046C (en) N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as axl inhibitors
JP6663866B2 (ja) リジン特異的なデメチラーゼ−１の阻害剤
JP2017501234A (ja) グルタミナーゼの新規阻害剤
CA3190653A1 (en) Bicyclic bromodomain inhibitors
WO2020227020A1 (en) Inhibitors of raf kinases
WO2023224998A1 (en) Inhibitors of parg
US11780862B2 (en) Inhibitors of MEK kinase
WO2022081469A1 (en) Inhibitors of raf kinases
CA3195859A1 (en) Inhaled formulations of pgdh inhibitors and methods of use thereof
KR20250012101A (ko) Parg의 억제제
AU2022406595B2 (en) Anti-apoptotic protein bcl-2 inhibitor, pharmaceutical composition and uses thereof
WO2025054260A1 (en) Inhibitors of mek kinase
WO2026060099A1 (en) Selective pi3k inhibitors
CN118047757A (zh) 吡啶氮氧化物类衍生物及其药物组合物、制备方法和用途
CN120136783A (zh) 吡啶氮氧化物类衍生物及其药物组合物、制备方法和用途

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 34 , NO 24 , PAGE(S) 3342 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME LIN BIOSCIENCE, LLC, APPLICATION NO. 2018380132, UNDER INID (71) CORRECT THE APPLICANT NAME TO LIN BIOSCIENCE, PTY LTD.

PC1 Assignment before grant (sect. 113)

Owner name: LIN BIOSCIENCE, INC.

Free format text: FORMER APPLICANT(S): LIN BIOSCIENCE, PTY LTD.

FGA Letters patent sealed or granted (standard patent)